Abstract CT058: TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors
Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Ana Oaknin(Hebron University), Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center), Kan Yonemori(National Cancer Centre Japan), Srikanth Gajavelli, Jimmy L. Zhao(California Institute of Technology), Justyna Filant(The University of Texas MD Anderson Cancer Center), Kristen K. Ciombor(Vanderbilt University Medical Center), Amit M. Oza(Ontario Institute for Cancer Research), Isabelle Ray‐Coquard(Centre Léon Bérard), Joshua M. Lang(University of Wisconsin–Madison), Rui‐Hua Xu(Sun Yat-sen University), Tina Hovey
Cited by 1
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k